Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Olema Pharmaceuticals, Inc. granted stock options to four new employees to purchase 33,600 shares of common stock, effective February 1, 2024. The options vest over four years, with a 10-year term and an exercise price of $15.25 per share. This move is in accordance with the 2022 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).

SAN FRANCISCO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to four new employees to purchase an aggregate of 33,600 shares of the Company's common stock, effective as of February 1, 2024. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan, with a grant date of February 1, 2024, as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $15.25 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on February 1, 2024. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.

Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Olema Oncology
Olema Oncology is a biopharmaceutical company committed to transforming the standard of care and improving outcomes for women living with cancer. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. In addition to our lead product candidate, palazestrant (OP-1250), a proprietary, orally-available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.

Contact:
Geoffrey Mogilner, Vice President, Investor Relations and Communications
ir@olema.com

FAQ

What is the news about Olema Pharmaceuticals, Inc. (OLMA) granting stock options to new employees?

Olema Pharmaceuticals, Inc. granted stock options to four new employees to purchase an aggregate of 33,600 shares of the Company's common stock, effective as of February 1, 2024.

How many shares can the new employees purchase through the stock options?

The new employees can purchase an aggregate of 33,600 shares of the Company's common stock through the stock options.

What is the vesting period for the stock options granted to the new employees?

The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years.

What is the exercise price of the stock options granted to the new employees?

The stock options have an exercise price of $15.25 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on February 1, 2024.

Under which plan were the stock options granted to the new employees?

The stock options were granted under the Company's 2022 Inducement Plan.

What is the term of the stock options granted to the new employees?

The stock options have a 10-year term.